Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Pharmacotherapeutic considerations in women with multiple sclerosis

Publikation: Bidrag til tidsskriftReviewpeer review

  1. The efficacy and safety of exenatide once weekly in patients with type 2 diabetes

    Publikation: Bidrag til tidsskriftReviewpeer review

  2. Treatment of adult short bowel syndrome patients with teduglutide

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Irinotecan and bevacizumab in recurrent glioblastoma multiforme

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Therapeutic management of type 1 diabetes before and during pregnancy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  5. Treating tension-type headache -- an expert opinion

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. COVID-19 in people with multiple sclerosis: A global data sharing initiative

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

INTRODUCTION: Multiple sclerosis (MS) is a chronically progressive disease of the central nervous system. The relapsing form of the disease predominantly affects women with onset between the ages 20 to 40 years. Therefore, timing, choice, and treatment options should take pregnancy planning into consideration to accommodate both the needs and safety of the mother and health of the fetus.

AREAS COVERED: In this review, the authors discuss and summarize the recent evidence of different pharmacotherapeutic possibilities in the treatment of women with MS.

EXPERT OPINION: There is evidence that disease modifying therapy reduces the risk of relapses and diminishes disability progression in people with relapsing MS. The disease is often diagnosed in the childbearing years, and thus pregnancy planning can possibly be a part of the pharmacotherapeutic considerations. The management of women planning pregnancy requires a balancing of risks. The clinician must consider the risks related to treatment discontinuation versus the risk of exposing the developing fetus to drugs that are potential fetotoxic. Randomized controlled trials of medication safety - if used during pregnancy, are prohibited for ethical reasons; hence, the evidence is continuously gathered from observational data, post-authorization studies and pregnancy registries.

OriginalsprogEngelsk
TidsskriftExpert Opinion on Pharmacotherapy
Vol/bind21
Udgave nummer13
Sider (fra-til)1591-1602
Antal sider12
ISSN1465-6566
DOI
StatusUdgivet - sep. 2020

ID: 61976062